

1 Risk factors for acquisition of meningococcal carriage 2 in the African meningitis belt

3 Authors

4 Laura V Cooper, University of Cambridge, Cambridge, UK

5 Anna Robson, University of Cambridge, Cambridge, UK

6 Caroline L Trotter, University of Cambridge, Cambridge, UK

7 Abraham Aseffa, Armauer Hansen Research Institute, Addis Ababa, Ethiopia

8 Jean-Marc Collard, Centre de Recherche Médicale et Sanitaire, Niamey, Niger; Bactériologie

9 expérimentale, Institut Pasteur de Madagascar, Antananarivo, Madagascar

10 Doumagoum Moto Daugla, Centre de Support en Santé Internationale, N'Djamena, Chad

11 Aldiouma Diallo, Institut de Recherche pour le Développement, Dakar, Senegal

12 Abraham Hodgson, Navrongo Health Research Centre, Navrongo, Ghana

13 Jean-François Jusot, Centre de Recherche Médicale et Sanitaire, Niamey, Niger

14 Babatunji Omotara, Department of Community Medicine, University of Maiduguri,

15 Maiduguri, Nigeria

16 Samba Sow, Centre pour les Vaccins en Développement, Bamako, Mali

17 Musa Hassan-King, Faculty of Infectious and Tropical Diseases, London School of Hygiene &

18 Tropical Medicine, London, UK

19 Olivier Manigart, Faculty of Infectious and Tropical Diseases, London School of Hygiene &
20 Tropical Medicine, London, UK

21 Maria Nascimento, Faculty of Infectious and Tropical Diseases, London School of Hygiene &
22 Tropical Medicine, London, UK

23 Arouna Woukeu, Faculty of Infectious and Tropical Diseases, London School of Hygiene &
24 Tropical Medicine, London, UK

25 Daniel Chandramohan, Faculty of Infectious and Tropical Diseases, London School of
26 Hygiene & Tropical Medicine, London, UK

27 Ray Borrow, Public Health England Vaccine Evaluation Unit, Manchester, UK

28 Martin CJ Maiden, University of Oxford, Oxford, UK

29 Brian Greenwood, Faculty of Infectious and Tropical Diseases, London School of Hygiene &
30 Tropical Medicine, London, UK

31 James M Stuart, Faculty of Infectious and Tropical Diseases, London School of Hygiene &
32 Tropical Medicine, London, UK

33

34 **on behalf of**

35 the MenAfriCar Consortium (*listed at end of manuscript)

36

37 **Key words:** acquisition, risk factors, *Neisseria meningitidis*, Africa

38 **Running title:** Risk factors for meningococcal acquisition

39 **Abstract word count:** 219

40 **Text word count:** 2560

41

42 **ABSTRACT**

43 Background

44 Although several studies of risk factors for prevalence of meningococcal carriage in the
45 African meningitis belt have been reported, few have examined risk factors for acquisition.
46 We investigated a range of potential risk factors for acquisition in seven countries of the
47 meningitis belt.

48 Methods

49 Households were followed up every two weeks for two months, then monthly for a further
50 four months. Pharyngeal swabs were collected from all available household members at each
51 visit and questionnaires completed. Risks of acquisition over the whole study period and for
52 each visit were analysed by a series of logistic regressions.

53 Results

54 Over the course of the study, acquisition was higher in: (i) 5-14 year olds, as compared with
55 those 30 years or older (OR 3.6, 95%CI 1.4-9.9); (ii) smokers (OR 3.6, 95%CI 0.98-13); and (iii)
56 those exposed to wood smoke at home (OR 2.6 95%CI 1.3-5.6). The risk of acquisition from
57 one visit to the next was higher in those reporting a sore throat during the dry season (OR
58 3.7, 95%CI 2.0-6.7) and lower in those reporting antibiotic use (OR 0.17, 95%CI 0.03-0.56).

59 Conclusions

60 Acquisition of meningococcal carriage peaked in school age children. Recent symptoms of
61 sore throat during the dry season, but not during the rainy season, were associated with a

- 62 higher risk of acquisition. Upper respiratory tract infections may be an important driver of
- 63 epidemics in the meningitis belt.

64 **BACKGROUND**

65 Epidemics of meningococcal meningitis occur periodically in the African Meningitis Belt, an
66 area of sub-Saharan Africa stretching from Senegal in the west to Ethiopia in the east.[1]
67 These epidemics are highly seasonal, with the majority of cases occurring during the dry
68 season, predominantly in the first five months of the year.[2] Given that asymptomatic
69 pharyngeal carriage of meningococci is relatively frequent (ranging from 3-30% of the
70 population)[3] and because meningococcal acquisition only occasionally leads to invasive
71 disease, one explanation for this striking seasonality is an increased risk of invasive disease in
72 the dry season, due to mucosal damage from environmental factors such as low absolute
73 humidity and dust.[1,4,5] Another hypothesis suggested by mathematical modelling is that
74 higher rates of meningococcal transmission during the dry season, combined with population
75 immunity, may be sufficient to explain epidemic patterns.[6] Although a review of carriage in
76 the meningitis belt published in 2007 found no evidence to support a seasonal effect on
77 carriage,[3] more recent studies have found a higher prevalence of carriage in the dry
78 season.[7,8]

79 Studies of carriage prevalence and acquisition will, therefore, lead to a better understanding
80 of the epidemiology of meningococcal meningitis in the African meningitis belt. The African
81 Meningococcal Carriage Consortium (MenAfriCar) undertook 20 cross-sectional carriage
82 surveys in seven African meningitis belt countries from July 2010 to July 2012, involving the
83 collection of over 48,000 pharyngeal swabs. These studies found a higher frequency of
84 carriage in children aged 5-14 years, in the dry season and in rural populations.[7] During
85 these surveys, households with at least one pharyngeal carrier of *N. meningitidis* were
86 recruited for longitudinal studies.[9]

87 Previous longitudinal studies in the meningitis belt have been undertaken mainly at the
88 population level [10–12] and few have investigated the transmission and acquisition of
89 carriage at an individual level.[13,14] The aim of this MenAfriCar study was to investigate a
90 comprehensive set of potential risk factors for the acquisition of carriage of *N. meningitidis*
91 across the African meningitis belt.

92 **METHODS**

93 *Household surveys*

94 Households included in this study were recruited during the course of cross-sectional surveys
95 conducted in seven countries in the African meningitis belt (Chad, Ethiopia, Ghana, Mali,
96 Niger, Nigeria and Senegal) in 2010, 2011, and 2012. Details of the survey methods employed
97 have been published previously.[7] Longitudinal surveys were triggered by the identification
98 of a putative carrier during a cross-sectional survey (Visit 0). This initial identification of
99 carriers relied on conventional microbiology and was later confirmed via molecular methods
100 at the University of Oxford. In some cases, molecular methods did not confirm the presence
101 of meningococci, so 51 of 184 households recruited to the study did not have an index carrier.

102 Within four weeks of the identification of a carrier, all members of the putative carrier's
103 household were invited to take part in further studies (Visit 1). The head of the household
104 was asked about characteristics of the household, including numbers of rooms and bedrooms,
105 sleeping arrangements, location of kitchen and cooking fuel, house construction, drinking
106 water, sanitation, and household assets such as vehicle ownership, livestock, and electrical
107 goods.

108 A pharyngeal swab sample was obtained from all members of a household who gave their
109 consent and a questionnaire completed which included questions on: smoking; social
110 activities; symptoms of recent respiratory tract infection; socio-economic status and
111 educational level; school attendance; travel history; recent medication including antibiotics;
112 meningitis vaccination; and ethnic group. Carrier households were followed up two-weekly
113 for two months (Visits 2-5) and monthly for a further four months (Visits 5-9). At each follow
114 up visit, each household member was asked for a pharyngeal swab sample and to answer a
115 short follow-up questionnaire on factors that might have changed since the previous visit,
116 such as symptoms of a respiratory tract infection.

117 *Laboratory methods*

118 Pharyngeal swab samples, taken from the posterior pharynx and tonsillar fossa *via* the mouth,
119 were plated directly onto Modified Thayer Martin agar plates in the field, taken to the
120 laboratory within six hours of collection, and processed as previously described.[9] A sample
121 of boiled suspensions of Gram negative oxidase positive bacteria was sent to the University
122 of Oxford for molecular analysis. Amplification and sequencing of the *rplF* gene was used to
123 confirm the presence of, and differentiate between, *Neisseria* species. Confirmed *N.*
124 *meningitidis* were further characterised by genogroup (including capsule null) and *porA*
125 genosubtype.

126 *Data management*

127 Data were managed using the Teleform system version 10.4.1 (Autonomy, Cambridge UK)
128 with a separate database module linking the main study database with genetic laboratory
129 results from the Oxford PubMLST.org/neisseria database (<https://pubmlst.org/neisseria>).
130 Data from the longitudinal questionnaires were merged using a common person ID, or census

131 number, person matching was checked, any duplicate entries were removed, and aberrant
132 values excluded.

133 *Statistical analysis*

134 The genogroup-specific acquisition rates and 95% confidence intervals were calculated as
135 Poisson rates, counting the number of acquisitions occurring in non-index carriers and the
136 time at risk as the days between the first carriage-negative swab and the first positive
137 swab. A series of fixed-effects logistic regressions were used to identify significant risk
138 factors for acquisition. In the first round of regressions, individual risk factors were included
139 in a multivariable logistic regression with the *a priori* variables sex, age group, and country.
140 In the second round, risk factors with $p < 0.1$ in round 1 were added to a single model with *a*
141 *priori* variables. In the third round, risk factors with $p < 0.05$ in round 2 were retained in the
142 multivariable model. In the fourth round, all factors dropped in round 3 were added back in
143 to the model one by one and all variables with $p < 0.05$ were retained, giving the final
144 models. The study-long and visit-by-visit models were then run with household ID and both
145 household and individual ID as random effects, respectively, to account for clustering, and
146 factors that were no longer significant ($p \geq 0.05$) were dropped.

147 Acquisition was assessed over the full study period (study-long) and visit-by-visit.

148 Individuals were defined as positive for study-long acquisition if they had a negative swab
149 (no meningococci isolated) at visits 0 or 1 and a positive swab (any meningococci isolated)
150 at any following visit. Individuals were defined as negative for study-long acquisition if they
151 had a negative swab at visits 0 or 1 and no positive swab at any subsequent visit.

152 Individuals with three or more missed visits in total were excluded, as the possibility of
153 acquisition during this missed period could not be ruled out, and individuals carrying at

154 visits 0 or 1 were also excluded.

155 Individuals were defined as positive for visit-by-visit acquisition on a given visit if the
156 individual had a positive swab at the current visit and a negative swab at the previous visit
157 or carried a different strain at the previous visit and the strain was not previously carried
158 during the study. Strains were assessed by genogroup and porA variable regions 1 and 2.

159 Individuals were defined as negative for visit-by-visit acquisition on a given visit if the
160 individual had a negative swab at the previous visit and a negative swab at the current visit.

161 Individuals carrying an identical strain to that obtained at the previous visit and individuals
162 who cleared carriage were excluded from the analysis. Tables S1 and S2 provide the
163 classification of cases for study-long and visit-by-visit acquisition.

164 We defined the dry season as January to May and the rainy season as June to December.

165 Because we found a significant association between sore throat and season and because
166 previous studies have demonstrated an interaction between meningococcal carriage, upper
167 respiratory tract infection, and season, we also tested for interaction between sore throat
168 and season in our final model and found that the model with an interaction term fitted
169 better than the model with no interaction (Table S4).

170 *Ethics*

171 The study was approved by the ethics committee of the London School of Hygiene and
172 Tropical Medicine and by the relevant ethical authorities in each African centre.[9] The head
173 of the household or another responsible adult gave verbal informed consent for the
174 household to be included in the study. Each individual recruited within that household gave
175 written informed consent; for children under the age of 18 years a parent or guardian gave
176 written consent and children aged over 12 years were additionally asked to give written
177 assent.

178 **RESULTS**

179 *Acquisition over course of the study*

180 Overall, 169/861 (20%) of non-index carriers became pharyngeal carriers of a
181 meningococcus at least once over the course of the study. A higher proportion of 5- to 14-
182 year-olds acquired carriage than other age groups, and a higher proportion of participants
183 acquired carriage in Senegal, Niger, Ghana, and Ethiopia relative to Chad and Mali (Table
184 1). A wide variation in acquisition rates was observed between countries. Genogroup W
185 and capsule-null (*cnI*) meningococci accounted for the majority (83%) of acquisitions. The
186 acquisition rates of genogroup W meningococci was 2.0% per month (95%CI 1.6-2.4)
187 double that of *cnI* meningococci at 1.0% per month (95%CI 0.74-1.4). Genogroups A, C, Y,
188 and other genogroup (i.e. other than A, B, C, W, X, Y or *cnI*) acquisitions were uncommon,
189 and no genogroup B or X acquisitions were detected.

190 In the final multivariable model, the highest odds of acquisition were among 5- to 14- year
191 olds, with odds in all age groups under 30 years of age being significantly higher than the
192 reference group of individuals 30 years and older (Table 1). Active smokers had higher odds
193 of acquiring carriage than non-smokers living in households with no smokers, with a lower
194 confidence bound just below 1 (OR 3.57 95%CI 0.98-12.99). Non-smokers living in
195 households with smokers also had elevated odds of acquisition but the difference was not
196 statistically significant. Wood was the ubiquitous cooking fuel, with 96% of participants
197 using this as cooking fuel; 56% of participants had additional wood smoke exposure.
198 Participants with household exposure to wood smoke (independent of using wood as
199 cooking fuel) had higher odds of acquiring carriage than those without (OR 2.60 95%CI
200 1.26-5.59). Although this trend was not significant in the regression analysis, higher

201 acquisition rates were observed in households with an indoor kitchen and in households
202 which used wood as the primary cooking fuel than in those who did not.

203 *Visit-specific Acquisition Analysis*

204 Participants who said they had had a sore throat since the previous visit during the dry season
205 were significantly more likely (OR 3.67 95%CI 1.95-6.65) to have acquired carriage in that time
206 period than those who did not have a sore throat in the rainy season (Table 2). Those who
207 reported taking antibiotics since the previous visit were significantly less likely (OR 0.169
208 95%CI 0.0271-0.564) to have acquired carriage.

209

210 **DISCUSSION**

211 This longitudinal study found a higher risk of acquisition amongst individuals who reported a
212 sore throat since the previous visit, but only during the dry season. An association between
213 an upper respiratory tract infection and meningococcal carriage has been reported
214 previously.[14] A sore throat could be due to an initial inflammation of the pharynx from
215 meningococcal colonisation or could be caused by a concurrent unrelated infection that
216 predisposes an individual to acquisition.[15] If the latter is true, upper respiratory tract
217 infections in combination with dust and low humidity may be an important driver for the
218 high risk of meningitis epidemics in the dry season. This hypothesis is supported by a recent
219 study indicating an association between upper respiratory tract infection (defined as otitis,
220 severe sore throat and rhinopharyngitis) and meningitis outbreaks in Burkina Faso.[16] Such
221 upper respiratory tract infections could plausibly increase both the risk of acquisition and
222 the risk of invasion after acquisition.

223

224 The 5-14 year-old age group had the highest acquisition rate. The highest prevalence of
225 carriage in cross-sectional MenAfriCar studies and in Burkina Faso in 2009 was similarly
226 highest in 5-14 year olds.[7,17] An overall acquisition rate of 2.4% (95% CI 1.6 to 4.0%) per
227 month was estimated from a longitudinal household study using a hidden Markov model.[9]
228 There were no significant differences reported by age group, but data were subdivided by
229 control and index households and there was no adjustment for other risk factors.

230 Additional factors linked to acquisition of meningococci over the course of this study were
231 smoking tobacco and exposure to wood smoke. Smoking, passive exposure to smoke and to
232 smokers has been shown to convey a high risk of carriage and invasive disease in industrialised
233 countries.[18–21] Exposure to cigarette smoke has also been linked to the risk of carriage in
234 the meningitis belt.[7,14] The higher risk of acquisition from smoke exposure in this study
235 suggests a direct risk from smoke itself, potentially from interference with mucosal immunity,
236 as exposure to wood smoke was an independent risk factor. Exposure to smoke from wood
237 fires has also been shown as a risk factor for meningococcal meningitis in northern Ghana.[22]
238 Although use of wood as primary cooking fuel was not found to be a significant risk factor,
239 this could be explained by the fact that nearly all study participants relied on wood as primary
240 fuel or that some households used outdoor kitchens, thus moderating the degree of
241 exposure.

242 Strengths of this study are the multi-centre design across seven countries of the meningitis
243 belt conducted at the same time, including a mix of urban and rural populations with a broad
244 age range, the use of standardised field and laboratory protocols and a large sample size.
245 Measuring acquisition rather than carriage ensures that the risk factors identified in this study
246 are not biased by factors associated with longer carriage duration. A comprehensive range of

247 risk factors was included, so that important confounding factors are unlikely to have been
248 missed; however, the sampling of carriers and non-carriers was not random and we would
249 expect some misclassification of carriage status from the known low sensitivity of pharyngeal
250 swabbing.

251 Both the acquisition of meningococci found in this longitudinal study and prevalence of
252 carriage in the MenAfriCar cross-sectional studies varied considerably by country. Although
253 laboratory methods were standardised across centres, differences in laboratory techniques
254 could still have contributed to some of the differences observed. As most meningococcal
255 acquisitions were either genogroup W or capsule-null and outside epidemics, it cannot be
256 assumed that risk factors for acquisition of other genogroups or during epidemics would be
257 the same as that found in this study.[23]

258 It was surprising that some risk factors such as household crowding that have long been
259 known to raise the risk of carriage and disease [7,13,24,25] were not associated in this study
260 with acquisition. Crowding was measured here by numbers sharing a bedroom or bedmat,
261 and by numbers of people per room in the household. It is possible that crowded living
262 conditions are so prevalent across the meningitis belt countries that any effect of crowding
263 on acquisition is not detectable. A study in rural Gambia did not find any differences in crowding
264 between compounds with and without cases of meningococcal meningitis during an
265 epidemic.[26]

266 Reported vaccination was clustered in particular time periods and countries corresponding to
267 the introduction of group A conjugate vaccine. Vaccination was not found to be protective
268 against carriage acquisition. However, we would not expect a group A conjugate vaccine to
269 have a significant impact on carriage in this study as very few group A carriers were detected.

270 We were not able to draw any conclusions regarding the relationship between carriage
271 acquisition and disease incidence because none of the study sites reported an outbreak of
272 meningitis during the follow-up period.

273 This study involved multiple countries and examined an exhaustive set of household and
274 individual risk factors for meningococcal acquisition. The importance of identifying these
275 risk factors is that acquisition is a necessary pre-requisite for invasive disease. Acquisition
276 studies also play a potential role in vaccine evaluation. Of particular interest for countries of
277 the African meningitis belt is the finding that symptoms of upper respiratory tract infection
278 are linked to risk of acquisition, but only in the dry season. The evidence is mounting that
279 such infections are an important factor behind the risk of epidemics in the meningitis belt.

280

281 ***Institutions and individual members of the MenAfriCar consortium who contributed to**
282 **this study**

283 Armauer Hansen Research Institute, Addis Ababa, Ethiopia: Oumer Ali, Abraham Aseffa (PI),
284 Ahmed Bedru, Tsehaynesh Lema, Tesfaye Moti, Yenenesh Tekletsion, Alemayehu Worku,
285 Haimanot Guebre Xabher (deceased), Lawrence Yamuah.

286 Centre de Recherche Médicale et Sanitaire (CERMES), Niamey, Niger (Member of the
287 International Network of Pasteur Institutes): Rahamatou Moustapha Boukary, Jean-Marc
288 Collard (PI), Ibrahim Dan Dano, Ibrahim Habiboulaye, Bassira Issaka, Jean-François Jusot,
289 Sani Ousmane, Issoufa Rabe.

290 Centre de Support en Santé International (CSSI), N'Djamena, Chad: Doumagoum Moto
291 Daugla (PI), Jean Pierre Gami, Kadidja Gamougam, Lodoum Mbainadji, Nathan Naibei,
292 Maxime Narbé, Jacques Toralta.

293 Centre pour les Vaccins en Développement, Bamako, Mali: Abdoulaye Berthe, Kanny Diallo,
294 Mahamadou Keita, Uma Onwuchekwa, Samba O Sow (PI), Boubou Tamboura, Awa Traore,
295 Alou Toure.

296 Centers for Disease Control, Atlanta, USA: Tom Clark, Leonard Mayer.

297 Department of Community Medicine, University of Maiduguri, Maiduguri, Nigeria: Mary
298 Amodu, Omeiza Beida, Galadima Gadzama, Babatunji Omotara (PI), Zailani Sambo, Shuaibu
299 Yahya.

300 Faculty of Infectious Disease, London School of Hygiene & Tropical Medicine, London, UK:
301 Daniel Chandramohan, Brian M Greenwood (PI), Musa Hassan-King, Olivier Manigart, Maria
302 Nascimento, James M Stuart, Arouna Woukeu.

303 Princeton University, USA: Nicole E Basta

304 Public Health England Vaccine Evaluation Unit, Manchester, UK: Xilian Bai, Ray Borrow,
305 Helen Findlow.

306 Institut de Recherche pour le Développement, Dakar, Senegal: Serge Alavo, Hubert Bassene,
307 Aldiouma Diallo (PI), Marietou Dieng, Souleymane Doucouré, Jules François Gomis, Assane
308 Ndiaye, Cheikh Sokhna, Jean François Trape.

309 Navrongo Health Research Centre, Navrongo, Ghana: Bugri Akalifa (deceased), Abudulai
310 Forgor (deceased), Abraham Hodgson (PI), Isaac Osei, Stephen L Quaye, John Williams, Peter
311 Wontuo.

312 University of Bristol, UK: Thomas Irving.

313 University of Cambridge, UK; Caroline L Trotter

314 University of Oxford, UK: Julia Bennett, Dorothea Hill, Odile Harrison, Martin CJ Maiden, Lisa
315 Rebbetts, Eleanor Watkins.

316 **Declarations**

317 **Ethics approval and consent to participate**

318 The study was approved by the ethics committee of the London School of Hygiene and
319 Tropical Medicine and by the relevant ethical authorities in each African centre. The head of
320 the household or another responsible adult gave verbal informed consent for the household
321 to be included in the study. Each individual recruited within that household gave written
322 informed consent; for children under the age of 18 years a parent or guardian gave written
323 consent and children aged over 12 years were additionally asked to give written assent.

324 **Consent for publication**

325 Not applicable.

326 **Availability of data and material**

327 The datasets generated and/or analysed during the current study are available in the
328 University of Cambridge Repository Apollo, [link to be made available upon acceptance of
329 manuscript].

330 **Competing interests**

331 The authors declare that they have no competing interests.

332 **Funding**

333 The work of the MenAfriCar Consortium was supported by grants from the Bill & Melinda
334 Gates Foundation and from the Wellcome Trust.

335 **Author contributions**

336 BMG, JMS, CLT, MN, RB, MCJM, AA, J-MC, J-FJ, DMD, BO, AD, SS, AH, AW designed the study
337 and coordinated the field work. AR, CLT, LVC, BMG, JMS drafted the manuscript. AR, CLT, and
338 LVC analysed data. All authors critically reviewed and approved the manuscript.

339 **Acknowledgements**

340 We thank the many individuals who participated in the household surveys reported in this
341 paper. The work described here also relied upon many staff, including fieldworkers and
342 laboratory technicians whom we thank for their contributions. We acknowledge the directors
343 of the African research centres for their support and the following individuals who provided
344 clinical monitoring: Ngandolo Bongo Narè (Chad), Frank Baiden (Ghana), Workeabeba Taye
345 (Ethiopia), Haoua Amadou (Niger and Mali), and Birahim Pierre Ndiaye (Senegal). The
346 guidance provided by the MenAfriCar Advisory Committee (Fred Binka, Mamadou Djingarey,
347 Robert Heyderman, Marie-Paule Kiene, Marie-Pierre Preziosi, David Stephens and Marcel

348 Tanner [chairman]) has been much appreciated. We also thank the following individuals who
349 contributed to the establishment of the MenAfriCar Consortium and to its activities in various
350 ways: William Perea (WHO, Geneva, Switzerland), Dominique Caugant (Norwegian Institute
351 of Public Health, Oslo, Norway), Mamadou Djingarey (WHO, Ouagadougou, Burkina Faso),
352 Marc LaForce (PATH, Seattle, USA), Judith Mueller (École des hautes études en santé
353 publique, Rennes, France), Gerd Pluschke (Swiss Tropical and Public Health Institute, Basle,
354 Switzerland), and Muhamed-Kheir Taha (Institut Pasteur, Paris, France), and other colleagues
355 from WHO and CDC who contributed. The work of the consortium across Africa would not
356 have been possible without the strong logistic support provided by members of the
357 MenAfriCar secretariat in London—Amit Bhasin, Elizabeth Huntley, Karen Williams, Lyanne
358 Wylde, and Karen Slater. Studies conducted in each country received full support from the
359 national health and local authorities and this is gratefully acknowledged.

360

361

362 Table 1. Risk factors for *N. meningitidis* acquisition over the full study period: single risk factor
 363 analysis and multi-variable model. Adjustment was made in both single and multi-variable analysis
 364 for age, country, and sex.

Factor	Single risk factor analysis				Multi-variable model			
	Total	Positive (%)	OR	95% CI	Total	Positive (%)	OR	95% CI
Age								
30 plus					205	11.7	1	
Under 5					91	28.6	3.12	(1.27,8.05)
5-14					108	23.1	3.62	(1.42,9.93)
15-29					161	21.1	2.38	(1.22,4.76)
Country								
Chad					54	5.6	1	
Ethiopia					64	26.6	7.65	(1.81,44.4)
Ghana					74	23	6.77	(1.52,40.1)
Mali					157	5.7	0.532	(0.110,3.22)
Niger					206	28.6	10.0	(2.53,57.3)
Senegal					10	40	13.3	(1.23,159)
Sex								
Female					326	17.5	1	
Male					239	21.8	1.00	(0.585,1.71)
Exposure to wood smoke in house (apart from use in cooking)*								
No	372	20.2	1		261	19.2	1	
Yes	478	19.0	2.74	(1.76,4.32)	304	19.4	2.60	(1.26,5.59)
Tobacco exposure*								
None	234	14.1	1		230	13.5	1	
Passive (secondhand) smoke	312	22.8	1.92	(0.965,3.77)	312	22.8	1.92	(0.823,4.55)
Active smoker	23	30.4	3.75	(1.23,10.8)	23	30.4	3.57	(0.978,13.0)§
Any sore throat reported *								
No	651	17.8	1					
Yes	208	25.5	1.66	(1.09,2.53)				
Any runny nose reported *								
No	184	20.7	1					
Yes	675	19.4	1.57	(0.995,2.51)				
Use gas as primary cooking fuel*								
No	832	20.0	1					
Yes	25	12.0	0.311	(0.0664,1.03)				
Completion of primary school (amongst over 17 years)*								
No	269	18.2	1					
Yes	99	11.1	0.381	(0.170,0.793)				
Household member completed secondary school*								
No	444	22.3	1					
Yes	415	16.9	0.670	(0.455,0.983)				
More than 2 participants per room*								
No	484	14.5	1					
Yes	375	26.4	1.44	(0.996,2.10)				

Factor	Single risk factor analysis				Multi-variable model			
	Total	Positive (%)	OR	95% CI	Total	Positive (%)	OR	95% CI
Attending primary school (ages 5 to 17)								
No	52	25	1					
Yes	254	23.2	0.721	(0.325,1.65)				
Regular social meetings								
None	202	20.3	1					
1-2 per week	68	16.2	0.916	(0.404,1.96)				
3-4 per week	48	8.3	0.531	(0.141,1.61)				
5-7 per week	52	5.8	0.356	(0.0793,1.14)				
Index carrier in household								
No	259	12.0	1					
Yes	600	23.0	1.32	(0.826,2.16)				
Use wood as primary cooking fuel								
No	31	12.9	1					
Yes	828	19.9	1.02	(0.340,3.83)				
Indoor kitchen								
No	660	16.4	1					
Yes	199	30.7	1.28	(0.838,1.94)				

365

366 NB Total number of individuals may not sum to 861 in every case because of missing values.

367 * p-value less than 0.1 in single risk factor analysis.

368 §p-value less than 0.05.

369

370 Table 2. Risk factors for visit-by-visit *N. meningitidis* acquisition: single risk factor analysis and multi-
 371 variable model. Adjustment was made a priori in both single and multi-variable analysis for age,
 372 country, and sex.

Factor	Single risk factor analysis (plus a priori)				Multi-variable model			
	Total	Positive (%)	OR	95% CI	Total	Positive (%)	OR	95% CI
Age								
30 plus					1504	1.8	1	
Under 5					1539	3.4	1.99	(1.22,3.32)
5-14					2129	4.2	2.76	(1.75,4.48)
15-29					1239	3	1.83	(1.08,3.15)
Country								
Chad					990	0.6	1	
Ethiopia					564	4.6	7.54	(2.59,24.5)
Ghana					828	3.5	5.7	(1.96,18.6)
Mali					1574	0.9	1.51	(0.483,5.13)
Niger					2281	5.2	11.5	(4.53,34.5)
Senegal					174	7.5	14.2	(3.6,60.7)
Sex								
Female					3405	2.9	1	
Male					3006	3.6	1.23	(0.907,1.68)
Antibiotic taken*								
No	6592	3.5	1		6150	3.3	1	
Yes	261	0.8	0.197	(0.0323,0.623)	261	0.8	0.169	(0.0271,0.564)
Interaction term*								
No sore throat, rainy	2643	3.3	1		2643	3.3	1	
No sore throat, dry	3481	2.8	0.88	(0.651,1.19)	3481	2.8	0.844	(0.617,1.16)
Sore throat, rainy	123	2.4	0.906	(0.218,2.52)	123	2.4	0.82	(0.192,2.39)
Sore throat, dry	164	11	3.72	(2.09,6.34)	164	11	3.67	(1.95,6.65)
Sore throat*								
No	6566	3.3	1					
Yes	287	7.3	2.64	(1.58,4.19)				
Season								
Rainy: June to December	1944	3.1	1					
Dry: January to May	4467	3.3	1.07	(0.78,1.47)				
Meningitis vaccination								
No	5743	3.7	1					
Yes	1110	2	1.54	(0.899,2.55)				
Attendance at social event								
No	3319	4.4	1					
Yes	3534	2.5	0.851	(0.63,1.14)				
Travel greater than one hour								
No	6055	3.6	1					
Yes	798	2	0.955	(0.538,1.58)				
Cough								
No	5163	3.6	1					
Yes	1690	3	0.955	(0.682,1.31)				
Runny nose								
No	4634	3.8	1					
Yes	2219	2.6	0.961	(0.689,1.32)				

373 * p-value less than 0.1 in single risk factor analysis.

374

375 Table S1. *Case definition for study-long acquisition.*

Classification	Carriage at visits 0 or 1	Carriage at visits 2-9	More than 3 missed visits	Number of individuals
Not acquisition	No	No	No	692
Acquisition	No	Yes	No	169
Excluded	No	No	Yes	231
Excluded	No	Yes	Yes	18
Excluded	Yes	No	No	42
Excluded	Yes	No	Yes	18
Excluded	Yes	Yes	No	159
Excluded	Yes	Yes	Yes	22

376

377 Table S2. *Case definition for visit-by-visit acquisition.*

Classification	Carriage at previous visit	Carriage at current visit	Strain previously observed	Number of visit pairs
Not acquisition	No	No	Not applicable	6768
Acquisition	No	Yes	No	226
Acquisition	Yes	Yes	No	47
Excluded	No	Yes	Yes	183
Excluded	Yes	Yes	Yes	366
Excluded	No	No data	Not applicable	1180
Excluded	Yes	No	Not applicable	516
Excluded	Yes	No data	Not applicable	128
Excluded	No data	No	Not applicable	1677
Excluded	No data	Yes	Not applicable	304
Excluded	No data	No data	Not applicable	2115

378

379 Table S3. *Odds of sore throat adjusting for age, country, sex and season.*

Factor	Total	Percent reporting sore throat	OR	95% CI
Age				
30 plus	2024		6.6	1
Under 5	1914		2.4	0.372 (0.261,0.522)
5-14	2806		2.6	0.399 (0.295,0.534)
15-29	1752		7.4	1.13 (0.873,1.45)
Country				
Chad	1038		5.8	1
Ethiopia	940		7.1	1.27 (0.883,1.83)
Ghana	1135		8.6	1.41 (1.01,1.98)
Mali	1854		1.1	0.174 (0.101,0.287)
Niger	3179		4.3	0.728 (0.532,1.01)
Senegal	350		0	
Sex				
Female	4424		4.3	1
Male	4072		4.6	1.14 (0.92,1.4)
Season				
Rainy: June to December	3617		4.4	1
Dry: January to May	4879		4.5	1.27 (1.02,1.57)

380

381

382 Table S4. Likelihood ratio test comparing visit-by-visit model with and without term of interaction
 383 between season and sore throat.

Model	Degrees of freedom	AIC	BIC	Log-likelihood	Deviance	Chi-square		
						Statistic	Degrees of freedom	p-value
Acquisition ~ Age + Country + Sex + Sore throat + Antibiotic	14	1660	1754	-815.82	1631.6			
Acquisition ~ Age + Country + Sex + Sore throat + Antibiotic + Season	15	1662	1763	-815.77	1631.5	0.099	1	0.75
Acquisition ~ Age + Country + Sex + Sore throat + Antibiotic + Season + Season and sore throat interaction	16	1656	1764	-811.97	1623.9	7.6	1	0.006

384

385

386 **References**

387 1. Greenwood B, Manson {Lecture}: {Meningococcal} meningitis in {Africa}. *Trans R Soc Trop Med Hyg* [Internet]. **1999** [cited 2014 Oct 26]; 93(4):341–353. Available from:
 388 <http://trstmh.oxfordjournals.org/content/93/4/341>
 389

390 2. Lingani C, Bergeron-Caron C, Stuart JMM, et al. Meningococcal {Meningitis}
 391 {Surveillance} in the {African} {Meningitis} {Belt}, 2004–2013. *Clin Infect Dis* [Internet]. **2015** [cited 2016 May 30]; 61(suppl 5):S410–S415. Available from:
 392 http://cid.oxfordjournals.org/content/61/suppl_5/S410
 393

394 3. Trotter CL, Greenwood BM. Meningococcal carriage in the {African} meningitis belt. *Lancet Infect Dis* [Internet]. **2007** [cited 2014 Oct 4]; 7(12):797–803. Available from:
 395 <http://www.sciencedirect.com/science/article/pii/S1473309907702888>
 396

397 4. Molesworth AM, Thomson MC, Connor SJ, et al. Where is the meningitis belt?
 398 {Defining} an area at risk of epidemic meningitis in {Africa}. *Trans R Soc Trop Med Hyg*
 399 [Internet]. **2002** [cited 2017 Apr 21]; 96(3):242–249. Available from:
 400 <http://www.sciencedirect.com/science/article/pii/S0035920302900891>

401 5. Jusot J-F, Neill DR, Waters EM, et al. Airborne dust and high temperatures are risk
 402 factors for invasive bacterial disease. *J Allergy Clin Immunol* [Internet]. **2017** [cited
 403 2017 May 24]; 139(3):977–986.e2. Available from:
 404 <http://www.sciencedirect.com/science/article/pii/S0091674916306169>

405 6. Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal meningitis in the
 406 {African} meningitis belt. *Epidemiol Infect* [Internet]. **2012** [cited 2014 Sep 26];
 407 140(05):897–905. Available from:
 408 http://journals.cambridge.org/article_S0950268811001385

- 409 7. MenAfriCar Consortium. The {Diversity} of {Meningococcal} {Carriage} {Across} the
410 {African} {Meningitis} {Belt} and the {Impact} of {Vaccination} {With} a {Group} {A}
411 {Meningococcal} {Conjugate} {Vaccine}. *J Infect Dis* [Internet]. **2015** [cited 2015 May
412 6]; 212(8):1298–1307. Available from:
413 <http://jid.oxfordjournals.org/content/212/8/1298>
- 414 8. Kristiansen PA, Diomandé F, Wei SC, et al. Baseline {Meningococcal} {Carriage} in
415 {Burkina} {Faso} before the {Introduction} of a {Meningococcal} {Serogroup} {A}
416 {Conjugate} {Vaccine}. *Clin Vaccine Immunol* [Internet]. **2011** [cited 2015 Mar 31];
417 18(3):435–443. Available from:
418 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067389/>
- 419 9. MenAfriCar Consortium. Household transmission of *Neisseria meningitidis* in the
420 African meningitis belt: a longitudinal cohort study. *Lancet Glob Heal* [Internet]. The
421 Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
422 license; **2016**; 4(12):e989–e995. Available from: [http://dx.doi.org/10.1016/S2214-](http://dx.doi.org/10.1016/S2214-109X(16)30244-3)
423 [109X\(16\)30244-3](http://dx.doi.org/10.1016/S2214-109X(16)30244-3)
- 424 10. Leimkugel J, Hodgson A, Forgor AA, et al. Clonal {Waves} of {Neisseria} {Colonisation}
425 and {Disease} in the {African} {Meningitis} {Belt}: {Eight}- {Year} {Longitudinal} {Study}
426 in {Northern} {Ghana}. *PLoS Med* [Internet]. **2007** [cited 2014 Oct 7]; 4(3):e101.
427 Available from: <http://dx.doi.org/10.1371/journal.pmed.0040101>
- 428 11. Mueller JE, Sangaré L, Njanpop-Lafourcade B-M, et al. Molecular {Characteristics} and
429 {Epidemiology} of {Meningococcal} {Carriage}, {Burkina} {Faso}, 2003. *Emerg Infect*
430 *Dis* [Internet]. **2007** [cited 2016 Nov 28]; 13(6):847–854. Available from:
431 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792846/>
- 432 12. Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the {Serogroup} {A}
433 {Meningococcal} {Conjugate} {Vaccine}, {MenAfriVac}, on {Carriage} and {Herd}
434 {Immunity}. *Clin Infect Dis* [Internet]. **2012** [cited 2015 May 6]; :cis892. Available
435 from: <http://cid.oxfordjournals.org/content/early/2012/11/16/cid.cis892>
- 436 13. Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM. The
437 {Epidemiology} of {Infections} {Due} to {Neisseria} meningitidis and {Neisseria}
438 lactamica in a {Northern} {Nigerian} {Community}. *J Infect Dis* [Internet]. **1982** [cited
439 2016 Mar 15]; 146(5):626–637. Available from:
440 <http://jid.oxfordjournals.org/content/146/5/626>
- 441 14. Mueller JE, Yaro S, Madec Y, et al. Association of respiratory tract infection symptoms
442 and air humidity with meningococcal carriage in Burkina Faso. *Trop Med Int Heal*
443 [Internet]. **2008** [cited 2015 Oct 28]; 13(12):1543–1552. Available from:
444 <http://doi.wiley.com/10.1111/j.1365-3156.2008.02165.x>
- 445 15. Bergh MR van den, Biesbroek G, Rossen JWA, et al. Associations between pathogens
446 in the upper respiratory tract of young children: interplay between viruses and
447 bacteria. *PLoS One* [Internet]. Public Library of Science; **2012**; 7(10):e47711. Available
448 from: <http://www.ncbi.nlm.nih.gov/pubmed/23082199>
- 449 16. Mueller JE, Woringer M, Porgho S, et al. The association between respiratory tract

- 450 infection incidence and localised meningitis epidemics: an analysis of high-resolution
451 surveillance data from Burkina Faso. *Sci Rep* [Internet]. Nature Publishing Group;
452 **2017**; 7(1):11570. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28912442>
- 453 17. Ba AK, Sanou I, Kristiansen PA, et al. Evolution of meningococcal carriage in
454 serogroups {X} and {Y} before introduction of {MenAfriVac} in the health district of
455 {Kaya}, {Burkina} {Faso}. *BMC Infect Dis* [Internet]. **2014** [cited 2015 May 6]; 14.
456 Available from:
457 [http://search.proquest.com/docview/1613626943/abstract/4F9A8C25CFF74B71PQ/1](http://search.proquest.com/docview/1613626943/abstract/4F9A8C25CFF74B71PQ/1?accountid=13314)
458 [?accountid=13314](http://search.proquest.com/docview/1613626943/abstract/4F9A8C25CFF74B71PQ/1?accountid=13314)
- 459 18. MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in
460 British teenagers. *Emerg Infect Dis* [Internet]. Centers for Disease Control and
461 Prevention; **2006**; 12(6):950–957. Available from:
462 <http://www.ncbi.nlm.nih.gov/pubmed/16707051>
- 463 19. Coen PG, Tully J, Stuart JM, Ashby D, Viner RM, Booy R. Is it exposure to cigarette
464 smoke or to smokers which increases the risk of meningococcal disease in teenagers?
465 *Int J Epidemiol* [Internet]. Oxford University Press; **2006** [cited 2018 Dec 12];
466 35(2):330–336. Available from:
467 [http://academic.oup.com/ije/article/35/2/330/694745/Is-it-exposure-to-cigarette-](http://academic.oup.com/ije/article/35/2/330/694745/Is-it-exposure-to-cigarette-smoke-or-to-smokers)
468 [smoke-or-to-smokers](http://academic.oup.com/ije/article/35/2/330/694745/Is-it-exposure-to-cigarette-smoke-or-to-smokers)
- 469 20. Stuart J, Robinson P, Cartwright KV, Noah N. EFFECT OF SMOKING ON
470 MENINGOCOCCAL CARRIAGE. *Lancet* [Internet]. Elsevier; **1989** [cited 2018 Dec 12];
471 334(8665):723–725. Available from:
472 <https://www.sciencedirect.com/science/article/pii/S0140673689907812>
- 473 21. Lee C-C, Middaugh NA, Howie SRC, Ezzati M. Association of Secondhand Smoke
474 Exposure with Pediatric Invasive Bacterial Disease and Bacterial Carriage: A
475 Systematic Review and Meta-analysis. Lanphear BP, editor. *PLoS Med* [Internet].
476 Public Library of Science; **2010** [cited 2018 Dec 12]; 7(12):e1000374. Available from:
477 <http://dx.plos.org/10.1371/journal.pmed.1000374>
- 478 22. Hodgson A, Smith T, Gagneux S, et al. Risk factors for meningococcal meningitis in
479 northern {Ghana}. *Trans R Soc Trop Med Hyg* [Internet]. **2001** [cited 2015 Oct 28];
480 95(5):477–480. Available from:
481 [http://trstmh.oxfordjournals.org/cgi/doi/10.1016/S0035-9203\(01\)90007-0](http://trstmh.oxfordjournals.org/cgi/doi/10.1016/S0035-9203(01)90007-0)
- 482 23. Collard J-M, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal
483 meningitis in {Niger} from 2008 to 2011 and the impact of vaccination. *BMC Infect Dis*
484 [Internet]. **2013** [cited 2015 Mar 31]; 13:576. Available from:
485 [http://search.proquest.com/docview/1467564250/abstract/33E3CA3C02014919PQ/](http://search.proquest.com/docview/1467564250/abstract/33E3CA3C02014919PQ/1?accountid=13314)
486 [1?accountid=13314](http://search.proquest.com/docview/1467564250/abstract/33E3CA3C02014919PQ/1?accountid=13314)
- 487 24. Kaiser AB, Hennekens CH, Saslaw MS, Hayes PS, Bennett J V. Seroepidemiology and
488 Chemoprophylaxis of Disease Due to Sulfonamide-Resistant *Neisseria meningitidis* in
489 a Civilian Population. *J Infect Dis* [Internet]. Oxford University Press; **1974** [cited 2018
490 Dec 12]; 130(3):217–224. Available from: [https://academic.oup.com/jid/article-](https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/130.3.217)
491 [lookup/doi/10.1093/infdis/130.3.217](https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/130.3.217)

492 25. Glover JA. Observations on the Meningococcus Carrier-Rate in relation to density of
493 population in Sleeping Quarters. J Hyg (Lond) [Internet]. Cambridge University Press;
494 **1918** [cited 2018 Dec 12]; 17(4):367–79. Available from:
495 <http://www.ncbi.nlm.nih.gov/pubmed/20474661>

496 26. Greenwood BM, Greenwood AM, Bradley AK, et al. Factors influencing susceptibility
497 to meningococcal disease during an epidemic in {The} {Gambia}, {West} {Africa}. J
498 Infect. **1987**; 14(2):167–184.

499

500

501